BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15695300)

  • 1. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
    Rudge S; Hailwood S; Horne A; Lucas J; Wu F; Cundy T
    Rheumatology (Oxford); 2005 Jun; 44(6):813-8. PubMed ID: 15695300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
    J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of bone mineral density at the lumbar spine and femoral neck in juvenile chronic arthritis--a prospective one year followup study.
    Kotaniemi A; Savolainen A; Kröger H; Kautiainen H; Isomäki H
    J Rheumatol; 1998 Dec; 25(12):2450-5. PubMed ID: 9858444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial.
    Zein CO; Jorgensen RA; Clarke B; Wenger DE; Keach JC; Angulo P; Lindor KD
    Hepatology; 2005 Oct; 42(4):762-71. PubMed ID: 16175618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
    Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
    J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
    Högler W; Briody J; Moore B; Lu PW; Cowell CT
    Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
    Loftus J; Allen R; Hesp R; David J; Reid DM; Wright DJ; Green JR; Reeve J; Ansell BM; Woo PM
    Pediatrics; 1991 Sep; 88(3):428-36. PubMed ID: 1881719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
    Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats.
    Fuchs RK; Shea M; Durski SL; Winters-Stone KM; Widrick J; Snow CM
    Bone; 2007 Aug; 41(2):290-6. PubMed ID: 17544352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
    N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Musculoskeletal abnormalities of the tibia in juvenile rheumatoid arthritis.
    Felin EM; Prahalad S; Askew EW; Moyer-Mileur LJ
    Arthritis Rheum; 2007 Mar; 56(3):984-94. PubMed ID: 17328076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.